GPX4 and acute kidney injury: Recent reports highlight arctigenin as a potential therapeutic agent, demonstrating its efficacy in modulating the System Xc−/GSH/GPX4 pathway and inhibiting disruptions in Fe metabolism, thereby mitigating cisplatin‐induced cell death in AKI.